🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

200 mcg (167% DV)
✅ 1.7× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.2mg

Other Ingredients

Sunflower Oil Gelatin Glycerin Beeswax Dibasic Calcium Phosphate purified Water Sunflower Lecithin Caramel color

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use: As a dietary supplement, take one softgel per day with water.

⚠️ Warnings & Precautions

Warning: For adults only.

Consult your physician before using this or any product if you are pregnant or nursing, taking medication, especially blood-thinning medications, or have a medical condition.

Keep out of reach of children.

Do not use if seal is broken.

Contains soy and sulfites.

🧪 Formulation Notes

Natural Vitamin K-2 200 mcg per softgel

Contains soy and sulfites.

Additional Information

Store in a cool, dry place. Do not refrigerate.

Bone and cardiovascular health

Product Details

UPC / SKU 0 87614 02906 1
DSLD Entry Date 2019-06-24
Product Type Vitamin
Form Softgel Capsule
Brand Swanson
DSLD ID 204282
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →